CompletedNCT00363337
Aripiprazole for depression in bipolarity
About this title
Read the official source — NCT00363337Medication studyAges 18+United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- CincinnatiSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateAugust 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 31
- Sponsor
- Lindner Center of HOPE
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00363337
- Official title
Show the full official title
A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cincinnati
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Lindner Center of HOPE.
Did this study involve medication?
Yes. The study involved medication, including aripiprazole.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
